AU2003228933A1 - Zonisamide use in obesity and eating disorders - Google Patents

Zonisamide use in obesity and eating disorders

Info

Publication number
AU2003228933A1
AU2003228933A1 AU2003228933A AU2003228933A AU2003228933A1 AU 2003228933 A1 AU2003228933 A1 AU 2003228933A1 AU 2003228933 A AU2003228933 A AU 2003228933A AU 2003228933 A AU2003228933 A AU 2003228933A AU 2003228933 A1 AU2003228933 A1 AU 2003228933A1
Authority
AU
Australia
Prior art keywords
zonisamide
obesity
eating disorders
eating
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003228933A
Other languages
English (en)
Inventor
Julianne E. Jennings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Publication of AU2003228933A1 publication Critical patent/AU2003228933A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2003228933A 2002-05-06 2003-05-05 Zonisamide use in obesity and eating disorders Abandoned AU2003228933A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37844602P 2002-05-06 2002-05-06
US60/378,446 2002-05-06
US10/429,474 2003-05-02
US10/429,474 US20040029941A1 (en) 2002-05-06 2003-05-02 Zonisamide use in obesity and eating disorders
PCT/US2003/014459 WO2003092682A1 (en) 2002-05-06 2003-05-05 Zonisamide use in obesity and eating disorders

Publications (1)

Publication Number Publication Date
AU2003228933A1 true AU2003228933A1 (en) 2003-11-17

Family

ID=29406837

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003228933A Abandoned AU2003228933A1 (en) 2002-05-06 2003-05-05 Zonisamide use in obesity and eating disorders

Country Status (5)

Country Link
US (2) US20040029941A1 (https=)
EP (1) EP1503755A1 (https=)
JP (1) JP2005527599A (https=)
AU (1) AU2003228933A1 (https=)
WO (1) WO2003092682A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173082A1 (en) * 2002-05-17 2017-05-31 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US20050059718A1 (en) * 2003-02-21 2005-03-17 Hayato Miyachi Methods of using zonisamide as an adjunctive therapy for partial seizures
EP1617832B1 (en) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20050043773A1 (en) * 2003-08-21 2005-02-24 Ivan Lieberburg Methods of improving the safety of zonisamide therapy
US20050043704A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050043705A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154033A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154034A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154032A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154036A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154035A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154037A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
KR20060128995A (ko) * 2004-01-13 2006-12-14 듀크 유니버시티 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
CA2565154A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
WO2005113069A2 (en) * 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
CN110893181A (zh) 2012-06-06 2020-03-20 纳丙药业有限责任公司 治疗超重和肥胖症的方法
CA2917702A1 (en) 2013-07-18 2015-01-22 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CA3016810C (en) 2016-03-07 2024-04-02 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for administering ppar.gamma. agonists, surfactant peptides and phospholipids
CN111565707A (zh) 2017-06-14 2020-08-21 森玛治疗公司 用于递送治疗物的装置和方法
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US25038A (en) * 1859-08-09 Egg-beater or churn
US33965A (en) * 1861-12-17 Improvement in rifle-sights
US4172896A (en) * 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5853975A (en) * 1994-08-23 1998-12-29 Millennium Pharmaceuticals, Inc. Methods for identifying compositions for the treatment of body weight disorders, including obesity
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
AP1285A (en) * 1996-06-28 2004-06-24 Ortho Mcneil Pharm Inc Anticonvulsant sulfamate derivatives useful in treating obesity.
US6262049B1 (en) * 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
CN100548290C (zh) * 1999-02-24 2009-10-14 辛辛那提大学 氨基磺酸酯衍生物用于治疗冲动控制障碍的用途
MXPA01009893A (es) * 1999-04-01 2003-07-28 Esperion Therapeutics Inc Compuestos con eter, composiciones y usos de estos.
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6437147B1 (en) * 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
EP3173082A1 (en) * 2002-05-17 2017-05-31 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
KR20060128995A (ko) * 2004-01-13 2006-12-14 듀크 유니버시티 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물

Also Published As

Publication number Publication date
EP1503755A1 (en) 2005-02-09
JP2005527599A (ja) 2005-09-15
US20040029941A1 (en) 2004-02-12
WO2003092682A1 (en) 2003-11-13
US20050026977A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
AU2003228933A1 (en) Zonisamide use in obesity and eating disorders
AU2003300017A1 (en) Microprocessor and microprocessor operation
AU2003272187A1 (en) Novel nanoparticles and use thereof
AU2003271926A1 (en) Facilitating and authenticating transactions
MXPA03001050A (es) Dispositivo desacelerador de rotacion y utilizacion del mismo.
AU2002364051A1 (en) Anti-cancer combination and use thereof
AU2002354134A1 (en) Functional foods and drinks
EP1417338A4 (en) SIMPLE NUCLEOTIDE GENES AND POLYMORPHISMS ASSOCIATED WITH FOOD BEHAVIOR DISORDERS
AU2003218462A1 (en) Treatment of obesity and other disorders associated with excessive food intake
AU2003261926A1 (en) Slimming agents and foods and drinks comprising the same
AU2003209289A1 (en) Transposable elements in rice and methods of use
AU2003231827A1 (en) Pseudo-tissues and uses thereof
AU2003228356A1 (en) Methods and compositions for preventing obesity and obesity related disorders
AU2003293500A1 (en) Lactoferrin in the reduction of pain
AU2003284597A1 (en) Apoptosis-associated protein and use thereof
AU2003283938A1 (en) Use of certain compounds in treatment of obesity
AU2003301112A1 (en) Hand and fingernail cleaning apparatus
AU2003302173A1 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003292462A1 (en) Electronic device and use thereof
AU2003277642A1 (en) Mixing and pulverizing device
AU2002352281A1 (en) Device for delivering liquids for human consumption and other uses
AU2003220265A1 (en) Tamperproof and counterfeit-resistant structure
AU2002233709A1 (en) Computer body supporting device and personal computer
AU2003255726A1 (en) Releasable fastener and receptacle
AU2003238451A1 (en) Food and beverage warmer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase